2027 ICD-10-CM Diagnosis Code D47.1Chronic myeloproliferative disease

ICD-10-CM Codes›C00–D49›D37-D48›D47

ICD-10-CM D47.1
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

D47.1 is a billable ICD-10-CM diagnosis code for chronic myeloproliferative disease. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 820 through 825, 840 through 842. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 133 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Neoplasms of unspecified nature or uncertain behavior.

For Medicare Advantage risk adjustment, D47.1 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
D47.1
Billable Status
Yes — Valid for Submission
Code Describes
Chronic myeloproliferative disease
Short Description
Chronic myeloproliferative disease
Same as the full description in the CMS dataset.
Parent Code
D47
Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue

Code Classification

ChapterC00–D49Neoplasms
SectionD37-D48Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
CategoryD47Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
This CodeD47.1Chronic myeloproliferative disease

Medicare Risk Adjustment (HCC)Billing

D47.1 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 21— Lymphoma and Other Cancers
Payment HCC · PY 2027 one of 463 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.671
community, non-dual, aged · ranges 0.493–0.739 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, and HCC 20
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 48
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 48 · ESRD (V21): HCC 48 · ESRD (V24): HCC 48
ESRD V21 weights: 0.059 dialysis, 0.173–0.234 functioning graft · ESRD V24 weights: 0.063 dialysis, 0.192–0.358 functioning graft
Part D (RxHCC)
RxHCC 21 — Lymphomas and Other Hematologic Cancers
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Chronic eosinophilic leukemia
  • Chronic myeloproliferative disorder
  • Chronic neutrophilic leukemia
  • Glomerulopathy due to myeloproliferative disorder
  • Myelodysplastic/myeloproliferative disease
  • Myelodysplastic/myeloproliferative neoplasm, unclassifiable
  • Myeloproliferative disorder
  • Occlusion of microvasculature of skin caused by platelet plug
  • Occlusion of microvasculature of skin due to myeloproliferative disorder-associated platelet plugs
  • Thrombophilia due to myeloproliferative disorder
  • Undifferentiated myeloproliferative disease

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to D47.1: its own notes plus those printed at block D37-D48 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • Chronic neutrophilic leukemia
  • Myeloproliferative disease, unspecified

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

On D47.1 itself
  • atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
  • chronic myeloid leukemia BCR/ABL-positive (C92.1-)
  • myelofibrosis NOS (D75.81)
  • myelophthisic anemia (D61.82)
  • myelophthisis (D61.82)
  • secondary myelofibrosis NOS (D75.81)
From Block D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes applies to 137 codes
  • neoplasms of unspecified behavior (D49.-)

Notes

General instructions on how these codes are used.

From Block D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes applies to 137 codes
  • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name D47.1, its category, or a range that includes it.

Excludes1 6

These codes carry an Excludes1 note naming D47.1: they are not reported together with it, unless the two conditions are unrelated.

  • C92.1 Chronic myeloid leukemia, BCR/ABL-positive
    chronic myeloproliferative disease (D47.1)
  • D61.81 Pancytopenia
    pancytopenia (due to) (with) myeloproliferative disease (D47.1)
  • D61.82 Myelophthisis
    idiopathic myelofibrosis (D47.1)
  • D61.82 Myelophthisis
    primary myelofibrosis (D47.1)
  • D75.81 Myelofibrosis
    idiopathic myelofibrosis (D47.1)
  • D75.81 Myelofibrosis
    primary myelofibrosis (D47.1)

Code Also 1

These codes say D47.1 may also be needed to fully describe the condition. The note gives no sequencing direction.

  • D47.02 Systemic mastocytosis
    myeloproliferative syndrome (D47.1)

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO072
Neoplasms of unspecified nature or uncertain behavior
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Myeloproliferative Neoplasm

    a group of myeloid neoplasms that includes the following: chronic myeloid leukemia, bcr-abl1 positive; polycythemia vera; essential thrombocythemia; primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.

Patient EducationClinical

Bone Marrow Diseases

Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D47.1 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
238.76 Myelofi w myelo metaplas
Approximate The match is approximate rather than exact.
ICD-9-CM
238.79 Lymph/hematpoitc tis NEC
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About D47.1Overview

What is the ICD-10 code for chronic myeloproliferative disease?

The ICD-10-CM code for chronic myeloproliferative disease is D47.1 (sometimes written as D471). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is D47.1 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report chronic myeloproliferative disease on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does D47.1 group to?

When chronic myeloproliferative disease is the principal diagnosis on an inpatient stay, it groups to MS-DRG 841, 821, 822, 825, 842, 824, 840, 820, 823, with relative weights from 0.9948 to 6.2454 depending on complications. Higher weights mean higher Medicare reimbursement.

Is D47.1 a CC or MCC?

CMS lists D47.1 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 133 closely related codes in its exclusion list.

Can D47.1 be reported with a code from C92.2?

Not as a rule. The Excludes1 note on D47.1 lists "atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What HCC is D47.1?

D47.1 (chronic myeloproliferative disease) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 48 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 21.

Does D47.1 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, D47.1 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.